Assessment of drug effects on the cardiovascular system and on POMC neuronal activity was performed as described in Supplementary Information 1
Forget the idea that cardio on GLP-1 medications is the only requirement
The recent approval of tirzepatide, a dual GLP-1/GIP receptor agonist, indicates a growing recognition of the potential therapeutic benefit of GIP receptor activation
Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.
Ci tin cng ngh Triple Micro Fit Sheet vi cht liu 3 lp siu mng, gip mt n m st vo da, tng cng kh nng thm thu dng cht nhanh chng v th gin ti a
Either way, we found NIODs lack of a subscription option (and discount) rather disappointing, so we hope to see the company add one in the future
)
